Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

Recruiting N/A Interventional Study
Siewert Type II Adenocarcinoma of Esophagogastric Junction
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
236 (estimated)
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed gastroesophageal adenocarcinoma; 2. R0 resectable Siewert Ⅱ, cT2-3N0-3M0 (AJCC V8 TNM classification); 3. Have a performance status of 0 or 1 on the ECOG Performance Scale; 4. Age 18-80 years old, both men and women; 5. Estimated survival ≥6 months; 6…
Contacts

Yin Li, MD

+8601087788052

liyin@cicams.ac.cn

CONTACT